Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2005

View Archived Issues

Potential oxazolidine candidate for the treatment of diabetes

CKD-712 is a promising agent for the treatment of sepsis

Clinical data suggests perifosine may be effective in sarcoma

Enzo Biochem receives grant to conduct study of EGS-21 for fatty liver disease

HIV compound SPD-754 licensed to Avexa

Recordati acquires Merckle's branded pharmaceutical business in Germany

Additional phase III Ceplene study in AML required by FDA

Taxus Liberte paclitaxel-eluting coronary stent launched in 18 countries

Sumitomo to transfer Calsed sales to Nippon Kayaku

GSK and Galapagos enter asthma target discovery alliance

Intercell to move IC-51 vaccine against Japanese encephalitis virus into phase III

Phase IIa Tetrodin study completes enrollment

Pharmexa inlicenses Antigenics' QS-21 adjuvant

Mycograb compassionate use program

Zoniporide reported to induce protective effects after resuscitation from ventricular fibrillation

Pivotal phase III study of Bio-E-Gel completes enrollment

Recombinant influenza vaccine with simplified delivery tested in humans

Endpoint not met in phase IIb study of Fibrostat for hypertrophic scars

TAK-242 shows promise in the treatment of sepsis

sNDA submitted for Xyrem

TB4 to be studied in phase II trial for venous stasis ulcers

Antitumor effects found for MLN-518 in cells expressing different KIT mutations

Phase Ib/II trial of Exherin cleared to begin by Swiss Medic

Bosentan shows efficacy in the prevention of digital ulcers associated with scleroderma

New antibacterial oxazolidinones from Orchid

GFAT inhibitors for type 2 diabetes disclosed in patent

Cytovia reports protease inhibitors coronaviruses and SARS-CoV

JNK inhibitors for neurodegenerative disorders in early development at Eisai

GSK prepares and tests novel compounds for proliferative diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...